- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03910088
Pregabalin Versus Hydrocortisone for Postdural Puncture Headache After Spinal for Cesarean (PDPH)
November 7, 2019 updated by: Nesrine El-Refai, Cairo University
Oral Pregabalin Versus Intravenous Hydrocortisone in Treatment of Postdural Puncture Headache After Spinal Anesthesia for Elective Cesarean Section
Postdural puncture headache (PDPH) is a common complication after spinal anesthesia.
The role of pregabalin and hydrocortisone in the treatment of PDPH is unclear.
The aim of this work is to assess and compare the efficacy of both drugs in severe cases of PDPH after spinal anesthesia for elective cesarean section.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study will be done on 30 patient with PDPH with VAS score ≥ 5 after spinal anesthesia for elective cesarean section.
Patients will be divided into three groups: Control group (group C):will receive conventional treatment in the form of good oral hydration, 500 mg of acetaminophen plus 65 mg of caffeine oral tablets thrice daily, 3 cups of coffee daily, 50 mg of diclofenac potassium oral tablets twice daily and recumbent positioning for 48 hours.
Pregabalin group (group P): will receive the conventional treatment plus 100 mg of pregabalin oral tablet every 8 hours for 48 hours.
Hydrocortisone group (group H): will receive the conventional treatment plus 100 mg of hydrocortisone IV every 8 hours for 48 hours.
The three groups will be compared regarding the headache intensity using a visual analog scale.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Zamalek
-
Cairo, Zamalek, Egypt, 11586
- Cairo University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Patients who underwent elective cesarean section under spinal anesthesia.
- Patients aged 18 to 40 years old.
- Patients classified as ASA I or II.
Exclusion Criteria:
- Patients with known sensitivity to any of the used drugs.
- Patients classified as ASA III or more.
- Preeclampsia.
- Patients with a history of chronic headache or migraine Patients receiving pregabalin for chronic pain.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: control group
received conventional treatment in the form of good oral hydration, 500 mg of acetaminophen plus 65 mg of caffeine oral tablets thrice daily, 3 cups of coffee daily, 50 mg of diclofenac potassium oral tablets twice daily and recumbent positioning for 48 hours
|
giving a drug to relieve post-dural puncture headache
Other Names:
giving oral fluids to maintain good hydration
Other Names:
giving a drug to relieve post-dural puncture headache
giving a drug to relieve post-dural puncture headache
|
Active Comparator: Pregabalin
received the conventional treatment plus 100 mg of pregabalin oral tablet every 8 hours for 48 hours
|
giving a drug to relieve post-dural puncture headache
Other Names:
giving oral fluids to maintain good hydration
Other Names:
giving a drug to relieve post-dural puncture headache
giving a drug to relieve post-dural puncture headache
giving a drug to relieve post-dural puncture headache
|
Active Comparator: Hydrocortisone
received the conventional treatment plus 100 mg of hydrocortisone IV every 8 hours for 48 hours.
|
giving a drug to relieve post-dural puncture headache
Other Names:
giving oral fluids to maintain good hydration
Other Names:
giving a drug to relieve post-dural puncture headache
giving a drug to relieve post-dural puncture headache
Giving drug to relieve post-dural puncture headache
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of pain using Visual Analogue Scale
Time Frame: the first 48 hours following treatment
|
Headache intensity after 1 minute in upright position using the Visual Analogue Scale for pain assessment ranging from 0 to 10, with zero means no pain and 10 is the worst pain after 48 hours of treatment
|
the first 48 hours following treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of the amount of rescue drug
Time Frame: The first 48 hours following treatment
|
Total dose of nalbuphine given in each group..
|
The first 48 hours following treatment
|
incidence of side effects of the studied drug
Time Frame: the first 48 hours following treatment
|
incidence of Somnolence
|
the first 48 hours following treatment
|
incidence of side effect of the studied drug
Time Frame: the first 48 hours following treatment
|
incidence of dizziness
|
the first 48 hours following treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 20, 2019
Primary Completion (Actual)
June 30, 2019
Study Completion (Actual)
June 30, 2019
Study Registration Dates
First Submitted
April 2, 2019
First Submitted That Met QC Criteria
April 8, 2019
First Posted (Actual)
April 10, 2019
Study Record Updates
Last Update Posted (Actual)
November 12, 2019
Last Update Submitted That Met QC Criteria
November 7, 2019
Last Verified
November 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Headache Disorders
- Headache Disorders, Secondary
- Headache
- Post-Dural Puncture Headache
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Antipyretics
- Purinergic Antagonists
- Purinergic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Membrane Transport Modulators
- Anti-Anxiety Agents
- Anticonvulsants
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Phosphodiesterase Inhibitors
- Purinergic P1 Receptor Antagonists
- Central Nervous System Stimulants
- Acetaminophen
- Pregabalin
- Diclofenac
- Hydrocortisone
- Caffeine
Other Study ID Numbers
- CairoU11112017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post-Dural Puncture Headache
-
Örebro University, SwedenKarolinska InstitutetCompletedPost-dural Puncture Headache | Post-dural Puncture BackacheSweden
-
Hospices Civils de LyonTerminated
-
The First Affiliated Hospital of Zhengzhou UniversityCompleted
-
Sunnybrook Health Sciences CentreWithdrawnPost Dural Puncture Headache
-
Nordlandssykehuset HFNorwegian University of Science and Technology; Imperial College LondonCompleted
-
United States Naval Medical Center, PortsmouthCompleted
-
University of Sao Paulo General HospitalUnknown
-
Tel-Aviv Sourasky Medical CenterUnknownPost Dural Puncture HeadacheIsrael
-
The University of Texas Health Science Center,...WithdrawnPost-Lumbar Puncture HeadacheUnited States
-
McGill Universityfunding: McGill Emergency Medicine 2010 Grant CompetitionCompletedBackache | Post-lumbar Puncture HeadacheCanada
Clinical Trials on Acetaminophen
-
Massachusetts General HospitalCompletedPain, Postoperative | Infertility, FemaleUnited States
-
Kaveh Aslani, MDCompletedAirway Obstruction | Tonsillitis | Difficulty SwallowingUnited States
-
Taipei Medical University WanFang HospitalUnknownCervical Radiculopathy | Radicular Pain | Acute Neck Pain | Cervicobrachial PainTaiwan
-
Medical University of South CarolinaCompletedPain, PostoperativeUnited States
-
MallinckrodtTerminatedAcute Pain, PostoperativeUnited States
-
Duke UniversityCompletedOsteoarthritis | Acetaminophen | Arthroplasty, Hip ReplacementUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
-
Spectrum Health HospitalsTerminatedHip FractureUnited States
-
Babiash, Kimberly H., M.D.Unknown
-
Beth Israel Deaconess Medical CenterNational Center for Research Resources (NCRR); Harvard UniversityCompletedAcetaminophen Poisoning | Acetaminophen Metabolism | Drug Metabolism by ExcipientsUnited States